Terms of the deals were not disclosed at press time. Both transactions are currently expected to close in the first quarter of 2018. The acquisitions are subject to customary closing conditions, including US antitrust clearance. These transactions are expected to have no impact on earnings in 2018.
PCA Skin is a leader in medical-grade in-office and take-home skin care products, and has strong support from dermatologists, plastic surgeons and aestheticians.
EltaMD is a leading physician-dispensed sun care brand with a unique positioning around broad-spectrum, everyday use, physician-dispensed sunscreen.
Combined estimated 2017 net sales for PCA Skin and EltaMD approximate $100 million. Both brands are similar in size and are primarily sold through professional skin care channels and online. They are distributed in the US, China and certain other international markets. Colgate plans to continue to operate the brands independently after closing.
Colgate’s chairman, president and CEO Ian Cook commented, “PCA Skin and EltaMD form an exciting combination for Colgate’s entry into the professional skin care category. We are delighted that these high-growth, high-margin brands will strengthen our global personal care business. Their complementary product portfolios and sales forces, strong professional support and similar distribution channels will advance Colgate’s presence in the premium global skin care category. Furthermore, these businesses will benefit from Colgate’s decades long legacy of working with professional experts to deliver recommendations that benefit their patients.”